GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET

Company Participants

David Dodd – Chairman and Chief Executive Officer

Mark Reynolds – Chief Financial Officer

Mark Newman – Chief Scientific Officer

John Sharkey – Head, Business Development

Conference Call Participants

Jason McCarthy - Maxim Group

Jeff Kraws - Crystal Research

Kumarguru Raja - Brookline Capital Markets

Operator

Good afternoon and welcome everyone to the GeoVax Second Quarter 2022 Corporate Update Call. I’m Andrew with Chorus Call and will facilitate today's call. With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Mark Newman, PhD, Chief Scientific Officer; Kelly McKee, M.D., M.P.H, Chief Medical Officer; and John Sharkey, PhD, Vice President, Business Development. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner. GeoVax's vaccines will be safe for human use. GeoVax's vaccines will effectively prevent targeted infections in humans. GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed. GeoVax raises require capital to complete vaccine development. There is development of competitive products that maybe more effective or easier to use han GeoVax's products. GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission, including those set forth at risk factors in GeoVax's Form 10-K.

It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.

David Dodd

Thank you. Good afternoon everyone, thank you for participating in the 2022 second quarter update call. Second quarter represented an exciting and critical period for GeoVax and that we advance clinical stage development status within the two priority areas and COVID-19 vaccine development and cancer therapy. In addition, we continue to advance our preclinical development stage programs. We also successfully strengthened our balance sheet during a very difficult investment environment, especially for the biotech sector. Our mission is to improve lives worldwide preventing or treating some of the world's most challenging infectious diseases and cancers. Our pursuit is to deliver safe affordable products delivering increased value to shareholders and stakeholders, while providing motivating career development opportunities to members of our team.